Yegang Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yegang Ma has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Ke Xu
Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning Province, People's Republic of China
2 shared publicationsBin Liu
Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning Province, People's Republic of China
1 shared publicationMing Xu
Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110042, P.R. China
1 shared publicationRong He
Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110042, P.R. China
1 shared publicationYongkai Wu
Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110042, P.R. China
1 shared publication
Latest Publications
- Open Access
- 1 August 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 6699-6710
The tumor suppressive roles of ARHGAP25 in lung cancer cells
Aim: Several Rho GTPase-activating proteins (Rho GAPs) have been proved to serve as tumor suppressors in diverse human cancers. Among them, ARHGAP25 has also been found to be associated with hematopoietic cells and regulate phagocytosis. Little is known about the role of ARHGAP25 in lung cancer cells. Methods: Quantitative real-time PCR and Western blot were used to measure the expression levels of ARHGAP25. The ability of cell growth and mobility were measured by cell proliferation and Transwell assays. Chromatin immunoprecipitation and luciferase assay were conducted to identify the transcriptional regulation. Results: Lung cancer tissues had much lower expression level of ARHGAP25 compared to non-cancerous specimens as well as for lung cancer cells. Cell growth and mobility were strongly reduced when ARHGAP25 was overexpressed. Further, significantly negative correlation between ARHGAP25 expression and Wnt signaling pathway was observed. Overexpression of ARHGAP25 reduced the expression of β-catenin and matrix metalloproteinase-7. ARHGAP25 knockdown effect of increased abilities of cell proliferation, migration and invasion could be reversed by adding XAV939 inhibitor. The promoter site of ARHGAP25 could be bound with HOXA4. HOXA4 could regulate the transcriptional activity of ARHGAP25. Conclusions: This study suggests that ARHGAP25 may inhibit lung cancer cell growth, migration and invasion through Wnt/β-catenin signaling pathway and its transcriptional activity can be regulated by HOXA4.
- 1 August 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 6699-6710
Open AccessThe tumor suppressive roles of ARHGAP25 in lung cancer cells
Aim: Several Rho GTPase-activating proteins (Rho GAPs) have been proved to serve as tumor suppressors in diverse human cancers. Among them, ARHGAP25 has also been found to be associated with hematopoietic cells and regulate phagocytosis. Little is known about the role of ARHGAP25 in lung cancer cells. Methods: Quantitative real-time PCR and Western blot were used to measure the expression levels of ARHGAP25. The ability of cell growth and mobility were measured by cell proliferation and Transwell assays. Chromatin immunoprecipitation and luciferase assay were conducted to identify the transcriptional regulation. Results: Lung cancer tissues had much lower expression level of ARHGAP25 compared to non-cancerous specimens as well as for lung cancer cells. Cell growth and mobility were strongly reduced when ARHGAP25 was overexpressed. Further, significantly negative correlation between ARHGAP25 expression and Wnt signaling pathway was observed. Overexpression of ARHGAP25 reduced the expression of β-catenin and matrix metalloproteinase-7. ARHGAP25 knockdown effect of increased abilities of cell proliferation, migration and invasion could be reversed by adding XAV939 inhibitor. The promoter site of ARHGAP25 could be bound with HOXA4. HOXA4 could regulate the transcriptional activity of ARHGAP25. Conclusions: This study suggests that ARHGAP25 may inhibit lung cancer cell growth, migration and invasion through Wnt/β-catenin signaling pathway and its transcriptional activity can be regulated by HOXA4.
- 25 February 2019
- Published by Spandidos Publications in Oncology Reports
- Vol. 41 (4) , 2281-2288
ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells
Lung cancer, a leading cause of cancer-related deaths, is frequently diagnosed in both males and females worldwide. In the present study, the Ras homologue GTPase activation protein 6 (ARHGAP6), which belongs to the Rho GTPase-activating protein (RhoGAP) family, was found to have low expression in tumor tissues from patients with lung cancer, accompanied by high expression of matrix metalloproteinase-9 (MMP9) and vascular endothelial growth factor (VEGF). In A549 and H1299 cells, upregulation of ARHGAP6 inhibited tumor growth and metastasis and reduced the levels of MMP9, VEGF and p-STAT3, while the levels STAT3 were unchanged, as demonstrated by CCK-8, migration and invasion assays as well as western blot analysis. In addition, interleukin 6 (IL-6)-induced migration, invasion and MMP9 and VEGF expression, and STAT3 signaling activity were suppressed by ARHGAP6 upregulation. Based on these data, we concluded that ARHGAP6 is critically important in lung cancer progression and that upregulation of ARHGAP6 benefits the treatment and prevention of lung cancer, possibly through the suppression of MMP9, VEGF and STAT3 signaling activation.
- 25 February 2019
- Published by Spandidos Publications in Oncology Reports
- Vol. 41 (4) , 2281-2288
ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells
Lung cancer, a leading cause of cancer-related deaths, is frequently diagnosed in both males and females worldwide. In the present study, the Ras homologue GTPase activation protein 6 (ARHGAP6), which belongs to the Rho GTPase-activating protein (RhoGAP) family, was found to have low expression in tumor tissues from patients with lung cancer, accompanied by high expression of matrix metalloproteinase-9 (MMP9) and vascular endothelial growth factor (VEGF). In A549 and H1299 cells, upregulation of ARHGAP6 inhibited tumor growth and metastasis and reduced the levels of MMP9, VEGF and p-STAT3, while the levels STAT3 were unchanged, as demonstrated by CCK-8, migration and invasion assays as well as western blot analysis. In addition, interleukin 6 (IL-6)-induced migration, invasion and MMP9 and VEGF expression, and STAT3 signaling activity were suppressed by ARHGAP6 upregulation. Based on these data, we concluded that ARHGAP6 is critically important in lung cancer progression and that upregulation of ARHGAP6 benefits the treatment and prevention of lung cancer, possibly through the suppression of MMP9, VEGF and STAT3 signaling activation.